Brief: Urogen Pharma Reports Q4 And FY20 Financial Results
18/03/2021 12:38
March 18 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2020
FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS
* Q4 LOSS PER SHARE $1.38
* ANTICIPATES 2021 OPERATING EXPENSES IN THE RANGE OF $155
TO $170
MILLION
Source text for Eikon: ID:nBw4P98Gqa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors